Header image

Symposium 10: Resolution Pharmacology: From Basic Science to Translational Medicine

Tracks
Track 2
Wednesday, July 15, 2026
11:15 AM - 1:15 PM

Details

The acute inflammatory response is protective, defending the host against infection or injury. Ideally, it is self-limited, spatially and temporally controlled, with its resolution actively coordinated by endogenous agonists to restore tissue homeostasis. These agonists include specialized pro-resolving mediators (SPMs), signaling lipid molecules, and pro-resolving proteins like annexin A1, which collectively drive anti-inflammatory and pro-resolving actions. However, when inflammation is left unchecked, it can become chronic, driving diseases such as respiratory, cardiovascular, metabolic, and allergic conditions, as well as arthritis. This symposium will explore the pivotal role of unresolved inflammation in these diseases and highlight the latest therapeutic advances. Alongside SPMs, we will discuss emerging therapeutic innovations, including annexin-A1 mimetic peptides and FPR small-molecule agonists (e.g. BMS-986235, biased agonist Compound 17b). These innovative therapies not only promote inflammation resolution but also enhance SPM production, representing promising strategies for treating chronic inflammatory diseases.


Speaker

Agenda Item Image
Dr Chengxue Helena Qin
Monash University

Innovative Mechanisms in Vascular Biology: Harnessing Pathways of Inflammation Resolution

Biography

Laboratory Head in Cardiovascular Pharmacology at Monash University, currently holding the prestigious positions of National Heart Foundation Future Fellow and Monash Talent Accelerator Fellow. Upon completing her PhD at the Department of Pharmacology & Therapeutics and the School of Chemistry (University of Melbourne), Dr. Qin advanced her career with a post-doctoral position at the Baker Institute in 2011. Recognizing her talent and leadership, she was subsequently recruited to establish her independent laboratory within the Drug Discovery Biology Theme at the Monash Institute of Pharmaceutical Sciences in 2019. Previously, she served as an MRFF REDI Industry Fellow and Baker Fellow. Dr. Qin also plays an integral role on the Board of Directors of the Australasian Pharmacologists and Toxicology Society, the Global Academic Drug Discovery Consortium, and the Australian Cardiovascular Alliance Emerging Leader (Industry Engagement portfolio). Dr. Qin is an emerging leader in translational pharmacology, driven by a visionary pursuit to develop "pro-resolving medicines" for the treatment of cardiopulmonary diseases, one of the leading causes of death globally. Her research team is dedicated to pioneering innovative "pro-resolving" therapies, primarily focusing on advancing the pro-resolving GPCRs (e.g. FPR2) R&D program to bridge scientific discoveries with impactful clinical solutions. Dr. Qin's expertise spans molecular and integrative pharmacology, rational drug design, and the intricacies of commercialization. Her scholarly contributions have been featured in prestigious journals such as Nature Communications, Cardiovascular Research, Circulation, British Journal of Pharmacology, Journal of Medicinal Chemistry, and Pharmacology & Therapeutics etc. Dr. Qin has secured substantial research funding from prestigious organizations including the National Health and Medical Research Council, National Heart Foundation, National Drug Discovery Centre, Diabetes Australia, CASS Foundation, Therapeutic Innovation Australia, JDRF etc. Dr. Qin's outstanding leadership and scholarly achievements have been duly recognized through the receipt of over 20 prestigious awards, including the Hypertension Australia Mid-Career Award (2023), Monash Talent Accelerator Fellow (2023), MRFF-Industry Fellow (2021), Future Research Leader (2020), and the Asian Australian Leadership Award (Basic Scientist, 2019), among others.

Session chair

Hong Yong Peh
National University Of Singapore

Agenda Item Image
Chengxue Helena Qin
Monash University

loading